Principal Financial Group Inc Biotechnology

Principal Financial Group Inc

$172 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
MNKD Mannkind Corp	$1.17B	$1.19 Million 0.0% of portfolio	184,575	Q4 2024 New
ADPT Adaptive Biotechnologies Corp	$1.05B	$860,000 0.0% of portfolio	143,444	Q4 2024 New
ARDX Ardelyx, Inc.	$745M	$765,000 0.0% of portfolio	148,142	Q4 2024 New
MDXG Mimedx Group, Inc.	$759M	$579,000 0.0% of portfolio	60,226	Q4 2024 New
RVMD Revolution Medicines, Inc.	$3.22B	$548,000 0.0% of portfolio	12,533	Q4 2024 New
RPRX Royalty Pharma PLC	$14.3B	$513,000 0.0% of portfolio	20,116	Q4 2024 New
IONS Ionis Pharmaceuticals Inc	$4.03B	$476,000 0.0% of portfolio	13,616	Q4 2024 New
MDGL Madrigal Pharmaceuticals, Inc.	$5.16B	$472,000 0.0% of portfolio	1,530	Q4 2024 New
XERS Xeris Biopharma Holdings, Inc.	$559M	$383,000 0.0% of portfolio	113,217	Q4 2024 Added 10.49%
APLS Apellis Pharmaceuticals, Inc.	$2B	$290,000 0.0% of portfolio	9,094	Q4 2024 New
ACLX Arcellx, Inc.	$2.72B	$280,000 0.0% of portfolio	3,679	Q4 2024 New
RNA Avidity Biosciences, Inc.	$1.39B	$274,000 0.0% of portfolio	9,450	Q4 2024 New
SRRK Scholar Rock Holding Corp	$1.59B	$274,000 0.0% of portfolio	6,345	Q4 2024 New
PTCT Ptc Therapeutics, Inc.	$3.39B	$268,000 0.0% of portfolio	5,955	Q4 2024 New
FOLD Amicus Therapeutics, Inc.	$1.92B	$236,000 0.0% of portfolio	25,114	Q4 2024 New
NUVL Nuvalent, Inc.	$3.08B	$235,000 0.0% of portfolio	3,004	Q4 2024 New
HRTX Heron Therapeutics, Inc.	$219M	$173,000 0.0% of portfolio	113,560	Q4 2024 New
YMAB Y M Abs Therapeutics, Inc.	$205M	$173,000 0.0% of portfolio	22,197	Q4 2024 New
GERN Geron Corp	$480M	$157,000 0.0% of portfolio	44,565	Q4 2024 New
RXRX Recursion Pharmaceuticals, Inc.	$993M	$144,000 0.0% of portfolio	21,349	Q4 2024 New
BCRX Biocryst Pharmaceuticals Inc	$1.38B	$133,000 0.0% of portfolio	17,807	Q4 2024 New
OCUL Ocular Therapeutix, Inc	$563M	$114,000 0.0% of portfolio	13,420	Q4 2024 New
NVAX Novavax Inc	$469M	$97,000 0.0% of portfolio	12,187	Q4 2024 New
AUPH Aurinia Pharmaceuticals Inc.	$1.1B	$92,000 0.0% of portfolio	10,316	Q4 2024 New
ABUS Arbutus Biopharma Corp	$472M	$41,000 0.0% of portfolio	12,816	Q4 2024 New
IBRX Immunity Bio, Inc.	$989M	$29,000 0.0% of portfolio	11,593	Q4 2024 New
NUVB Nuvation Bio Inc.	$428M	$26,000 0.0% of portfolio	10,139	Q4 2024 New
ERAS Erasca, Inc.	$142M	$25,000 0.0% of portfolio	10,136	Q4 2024 New
TSHA Taysha Gene Therapies, Inc.	$60M	$25,000 0.0% of portfolio	14,971	Q4 2024 New
AKBA Akebia Therapeutics, Inc.	$379M	$22,000 0.0% of portfolio	12,221	Q4 2024 New
SANA Sana Biotechnology, Inc.	$314M	$20,000 0.0% of portfolio	12,499	Q4 2024 New
OCGN Ocugen, Inc.	$147M	$17,000 0.0% of portfolio	22,246	Q4 2024 New
XFOR X4 Pharmaceuticals, Inc	$13M	$11,000 0.0% of portfolio	14,491	Q4 2024 New
NKTR Nektar Therapeutics	$120M	$10,000 0.0% of portfolio	10,767	Q4 2024 New
LYEL Lyell Immunopharma, Inc.	$107M	$7,000 0.0% of portfolio	10,997	Q4 2024 New
LCTX Lineage Cell Therapeutics, Inc.	$69.6M	$6,000 0.0% of portfolio	13,700	Q4 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.